Searchable abstracts of presentations at key conferences in endocrinology

ea0070oc1.2 | Adrenal and Cardiovascular Endocrinology | ECE2020

A Phase III randomized, controlled trial of a modified-release hydrocortisone formulation in the treatment of classic congenital adrenal hyperplasia

Merke Deborah , Mallappa Ashwini , Arlt Wiebke , de la Perriere Aude Brac , Hirschberg Linden Angelica , Juul Anders , Newell-Price John , Perry Colin , Prete Alessandro , Rees Aled , Reisch Nicole , Stikkelbroeck Nike , Touraine Phillippe , Matlby Kerry , Treasure Peter , Porter John , Ross Richard

Background: Patients with classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency (21-OHD-CAH) have poor health outcomes due to failure of currently available glucocorticoid preparations to control adrenocorticotropic hormone-driven androgen excess. We investigated whether modified-release hydrocortisone (MR-HC), which mimics the physiological circadian cortisol rhythm, could improve androgen control.Methods: 122 patients with 21-OHD-CAH ...